Measurable residual disease in Philadelphia chromosome-positive disease, achieved with the BCR::ABL1 quantitative method, is the standard of care in CML and Ph+ acute leukemias [3,15]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.